



Büşra CESUR¹

Giriş

Nöropatik ağrı (NA), primer lezyon ya da bir hastalık sonucunda gelişebilen teşhisi ve tedavisi konusunda hala aşılması gereken zorlukları olan, devamlı nosiseptif uyarının görüldüğü karmaşık bir ağrı çeşididir (1). NA klinikte sıklıkla görülen bir hastalıktır (2). NA'nın, santral ve periferik mekanizmalardan kaynaklandığı bilinmektedir. Bunlar travma, sinir hasarı, enfeksiyonlar, kemoterapötikler, toksinler, vitamin eksiklikleri gibi periferik ya da inme, tümör, multiple skleroz gibi santral rahatsızlıklar olabilmektedir. NA, sıklıkla kronik olup ciddi epidemiyolojik bir sorun olarak karşımıza çıkmaktadır. NA'da hiperaljezi, allodini ve hiperpati gibi bulgular görülmektedir. NA duygu durumu bozukluklarına yol açar ve hastanın yaşam kalitesini düşürür (3). Antikonvülanlar, antidepressanlar, opioidler ve non opioidler NA tedavisinde kullanılsa da tam olarak etkinliği kanıtlanmış bir ilacın olmayışı, bu ağrının henüz aydınlatılmamış farklı mekanizmalardan meydana geldiğini düşündürmektedir. NA'nın, mekanizmasının yeterince aydınlatılamaması ve etkin bir tedavisinin olmayışı gibi sorunların aşılması için daha az yan etkili ve etkinliği yüksek ilaçların geliştirilmesine ihtiyaç duyulmaktadır. Bu nedenle, güncel bir problem haline gelen NA'nın anlaşılabilmesi yeni tedavi stratejilerinin geliştirilebilmesi için deneysel hayvan modellerine ihtiyaç duyulmaktadır (4). NA'nın patofizyolojisindeki farklılıklar nedeniyle pek çok NA modeli geliştirilmiştir. Bu modelleri periferik sinir hasarı, santral sinir sistemi hasarı, ilaçlara bağlı modeller, hastalık kaynaklı modeller ve geriye kalanlarını da diğer nöropati modelleri olarak sınıflandırmak mümkündür. Bu kitapta literatürde sıklıkla kullanılan deneysel nöropatik hayvan modelleri anlatılmıştır.

¹ Arş. Gör., Akdeniz Üniversitesi Tıp Fakültesi Tıbbi Farmakoloji AD., busracesur07@hotmail.com

Kaynaklar

1. Kankowski, S., et al., *Neuropathic pain: Spotlighting anatomy, experimental models, mechanisms, and therapeutic aspects*. European Journal of Neuroscience, 2021. 54(2): p. 4475-4496.
2. Scholz, J., et al., *The IASP classification of chronic pain for ICD-11: chronic neuropathic pain*. Pain, 2019. 160(1): p. 53-59.
3. Finnerup, N.B., et al., *Neuropathic pain: from mechanism to treatment*. Physiological reviews, 2021. 101(1): p. 259-301
4. Merskey, H. and N. Bogduk, *Descriptions of chronic pain syndromes and definition of pain term*. IASP Press (Seattle), 1994.
5. Raja S.N., et al., *Therevised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises*. Pain, 2020; 161(9): p. 1976-1982.
6. Treede, R.D., et al., *Neuropathic pain: redefinition and a grading system for clinical and research purposes*. Neurology, 2008. 70(18): p. 1630-1635.
7. Charak, S., et al., *Assessment and Management of Pain in Palliative Care*. Suggestions for Addressing Clinical and Non-Clinical Issues in Palliative Care, 2021. 167.
8. Şentürk, İ.A. *Ağrı Değerlendirilmesi: Tipleri Ve Mekanizmaları*. Medical Research Reports, 2018, 1(3), 78-81.
9. Bekircan-Kurt, C.E., et al., *Neuropathic Pain Frequency in Neurology Outpatients: A Multicenter Study*. Arch Neuropsychiatry, 2021. 58(4): p. 257-260.
10. Rosenberger, D.C., et al., *Challenges of neuropathic pain: focus on diabetic neuropathy*. Journal of Neural Transmission, 2020. 127(4): p. 589-624.
11. Luana, C., et al., *Neuropathic pain*. Nat. Rev. Dis. Primers, 2017. 3: 17.
12. Kösehasanoğulları, M., ve N. Yılmaz, *Fibromiyalji sendromu ve nöropatik ağrı*. Ege Tıp Bilimleri Dergisi, 2018. 1(1): p. 26-31.
13. Cavalli, E., et al., *The neuropathic pain: An overview of the current treatment and future therapeutic approaches*. International Journal of Immunopathology and Pharmacology, 2019. 33: 2058738419838383.
14. Bouali-Benazzouz, R., M. Landry, A. Benazzouz, and P. Fossat, *Neuropathic pain modeling: Focus on synaptic and ion channel mechanisms*. Progress in Neurobiology, 2021. 201: 102030.
15. Yam, M. F., Loh, Y. C., Tan, C. S., Khadijah Adam, S., Abdul Manan, N., & Basir, R. *General pathways of pain sensation and the major neurotransmitters involved in pain regulation*. International journal of molecular sciences, 2018. 19(8), 2164.
16. Iyengar S, Ossipov M.H, Johnson K.W. *The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine*. Pain 2017; 158(4): 543-559
17. Anthony P. Ford ve Bradley J. Udem. *The therapeutic promise of ATP antagonism at P2X3 receptors in respiratory and urological disorders*. Front. Cell. Neurosci. 2013; 7: 267.
18. Yücel, A., & A. Çimen, *Nöropatik ağrı: Mekanizmalar, tanı ve tedavi*. Ağrı, 2005. 17: 1.
19. Kami, K., F. Tajima, and E. Senba, *Exercise-induced hypoalgesia: potential mechanisms in animal models of neuropathic pain*. Anatomical science international, 2017. 92(1): p. 79-90.
20. Alvites, R., et al. *Peripheral nerve injury and axonotmesis: State of the art and recent advances*. Cogent Medicine, 2018. 5(1): p. 1466404.
21. Wall, P.D., et al. *Autotomy following peripheral nerve lesions: experimental anaesthesia/dolorosa*. Pain, 1979. 7(2): p. 103-11.
22. Amir, R., and M. Devor, *Ongoing activity in neuroma afferents bearing retrograde sprouts*. Brain Res, 1993. 630(1-2): p. 283-8.
23. HoKim, S., and J. MoChung, *An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in therat*. Pain, 1992. 50(3): p. 355-363
24. Ye, G.-L., et al., *Ligation of mouse L4 and L5 spinal nerves produces robust allodynia without major motor function deficit*. Behavioural Brain Research, 2015. 276: p. 99-110.
25. Gopalsamy, B., et al., *Experimental characterization of the chronic constriction injury-induced neuropathic pain model in mice*. Neurochemical Research, 2019. 44: p. 2123-2138.

26. Bennett, G.J., and Y.K. Xie, *A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man*. Pain, 1988. 33(1): p. 87-107.
27. Authier, N., et al., *An animal model of nociceptive peripheral neuropathy following re-peated cisplatin injections*. Experimental Neurology, 2003. 182(1): p. 12-20.
28. Ta, L. E., et al., *Mice with cis-platin and oxaliplatin-induced painful neuropathy develop distinct early responses to thermal stimuli*. Molecular Pain, 2009. 5(1): p. 1-11.
29. Takasaki, I., et al., *Allodynia and hyperalgesia induced by herpes simplex virus type- 1 infection in mice*. Pain, 2000. 86: p. 95-101.
30. Ahlgren S. C., and J.D. Levine, *Mechanical hyperalgesia in streptozotocin-diabetic rats*. Neuroscience, 1993. 52(4): p. 1049-1055.
31. Murakami, T., et al., *Development of sensory neuropathy in streptozotocin-induced diabetic mice*. Brain and Behavior, 2013. 3, p. 35-41
32. Wall, P.D., et al., *Autotomy following peripheral nerve lesions: experimental anaesthesia dolorosa*. Pain, 1979. 7(2): p.103-11.
33. Sacerdote, P., et al., *Transient early expression of TNF- α sciatic nerve and dorsal root ganglia in a mouse model of painful peripheral neuropathy*. Neurosci Lett, 2008. 436(2): p. 210-3.
34. Muthuraman, A., A.S. Jaggi, N. Singh, and D. Singh, *Ameliorative effects of amiloride and pralidoxime in chronic constriction injury and vincristine-induced painful neuropathy in rats*. Eur J Pharmacol, 2008. 587(1-3): p. 104-11.
35. Jaggi, A.S., V. Jain, and N. Singh, *Animal models of neuropathic pain*. Fundam Clin Pharmacol, 2011. 25(1): p. 1-28.
36. Seltzer, Z., R. Dubner, and Y. Shir, *A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury*. Pain, 1990. 43: p. 205-218.
37. Wang, L.X. and Z.J. Wang, *Animal and cellular models of chronic pain*. Adv Drug Deliv Rev, 2003. 55: p. 949-65.
38. Kim, S.H., J.M. Chung, *An Experimental Model For Peripheral Neuropathy Produced By Segmental Spinal Nerve Ligation In The Rat*. Pain, 1992. 50: p. 355- 363.
39. Jaggi, A.S., V. Jain, N. Singh, *Animal models of neuropathic pain*. Fundam Clin Pharmacol, 2011. 25(1): p. 1-28.
40. Kinnman, E., J.D. Levine, *Sensory and sympathetic contributions to nerve injury-induced sensory abnormalities in the rat*. Neuroscience, 1995. 64(3): p. 751-67.
41. La Buda, C.J., and P.J. Little, *Pharmacological evaluation of the selective spinal nerve ligation model of neuropathic pain in the rat*. J Neurosci Methods, 2005. 144(2): p. 175-81.
42. Yezierski, R.P. and S.H. Park, *The mechanosensitivity of spinal sensory neurons following intraspinal injections of quissuqualic acid in the rat*. Neurosci Lett, 1993. 157: p. 115-119.
43. Kumar, A. H.Kaur, and A. Singh, *Neuropathic pain models caused by damage to central or peripheral nervous system*. Pharmacol Rep, 2018. 70(2): p. 206-16.
44. Allen, A.R., *Surgery of experimental lesion of spinal cord equivalent to crush injury of fracture-dislocation of spinal column*. J Am Med Assoc, 1911. p. 57.
45. Siddall, P.J., C.L. Xu, and M.J. Cousins, *Allodynia following traumatic spinal cord injury in the rat*. Neuroreport, 1995. 6(9): p. 1241-4.
46. Drew, G.M., P.J. Siddall, and A.W. Duggan, *Responses of spinal neurons to cutaneous and dorsal root stimuli in rats with mechanical allodynia after contusive spinal cord injury*. Brain Res, 2001. 893(1-2): p. 59-69.
47. Watson, B.D., et al., *Photochemically induced spinal cord injury in the rat*. Brain Res, 1986. 367(1-2): p. 296-300.
48. Gaviria, M., et al., *A mouse model of acute ischemic spinal cord injury*. J Neurotrauma, 2002. 19(2): p. 205-21.
49. Prado, R., et al., *Photochemically induced graded spinal cord infarction. Behavioral, electrophysiological, and morphological correlates*. J Neurosurg, 1987. 67(5): p. 745-53.
50. Xu, X.J., et al., *Wiesefeld-Hallin Z. Chronic pain-related syndrome in rats after ischemic spinal cord lesion: a possible animal model for pain in patients with spinal cord injury*. Pain, 1992. 48(2): p. 279-90.

51. Hao, J.X., et al., *Photochemically induced transient spinal ischemia induces behavioral hypersensitivity to mechanical and cold stimuli, but not to noxious-heat stimuli, in the rat*. Exp Neurol, 1992. 118(2): p. 187-94.
52. Christensen, M.D., et al., *Mechanical and thermal allodynia in chronic central pain following spinal cord injury*. Pain, 1996. 68(1): p. 97-107.
53. Kim, J., et al., *Cold and mechanical allodynia in both hind paws and tail following thoracic spinal cord hemisection in rats: Time courses and their correlates*. Neurosci Lett, 2003. 343(3): p. 200-4.
54. Klit, H., N.B. Finnerup, and T.S. Jensen, *Central post-stroke pain: clinical characteristics, pathophysiology, and management*. Lancet Neurol, 2009. (8): p. 857-868.
55. Lu, H.F., et al., *A new central post-stroke pain rat model: autologous blood injected thalamic hemorrhage involved increased expression of P2X4 receptor*. Neurosci. Lett, 2018. 687: p. 124-130.
56. Gritsch, S., et al., *Functional characterization of a mouse model for central post-stroke pain*. Molecular Pain, 2016. 12: 1744806916629049.
57. Dickinson, B. D., et al., *Maldynia: Pathophysiology and management of neuropathic and maladaptive pain—A report of the AMA Council on Science and Public Health*. Pain Medicine, 2010. 11(11): p. 1635-1653.
58. Authier, N., et al., *Assessment of allodynia and hyperalgesia after cisplatin administration to rats*. Neurosci Lett, 2000. 291: p. 73-76.
59. Pennypacker, S.D., et al., *Methods and protocols for chemotherapy-induced peripheral neuropathy (CIPN) mouse models using paclitaxel*. Methods in Cell Biology, Academic Press Inc., 2022.
60. Aley, K.O., D.B. Reichling, and J.D. Levine, *Vincristine hyperalgesia in the rat: a model of painful vincristine neuropathy in humans*. Neuroscience, 1996. 73: p. 259-265.
61. Authier, N., et al., *Description of a short-term taxol-induced nociceptive neuropathy in rats*. Brain Res, 2000. 887: p. 239-249.
62. Ledebøer, A., et al., *Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats*. Brain Behav Immun, 2007. 21(5): p. 686-98.
63. Flatters, S.J., and G.J. Bennett, *Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: Evidence for mitochondrial dysfunction*. Pain, 2006. 122(3): p. 245-57.
64. Polomano, R.C., et al., *A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel*. Pain, 2001. 94(3): p. 293-304.
65. Ledebøer, A., et al., *Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats*. Brain Behav Immun, 2007. 21(5): p. 686-98.
66. Argyriou, A.A., et al., *Chemotherapy-induced peripheral neuropathy in adults: A comprehensive update of the literature*. Cancer Manag Res, 2014. 6: p. 135-47.
67. Cece, R., et al., *An ultrastructural study of neuronal changes in dorsal root ganglia (DRG) of rats after chronic cisplatin administrations*. Histochem J, 1995. 27(4): p. 837-45.
68. Vera, G., et al., *WIN 55,212-2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the rat*. Life Sci, 2007. 81(6): p. 468-79.
69. Grolleau, F., et al., *A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels*. Journal of Neurophysiology, 2001. 85(5): p. 2293-2297.
70. Joseph, E.K., et al., *Sexual dimorphism for protein kinase C epsilon signaling in a rat model of vincristine-induced painful peripheral neuropathy*. Neuroscience, 2003. 119(3): p. 831-8.
71. Tanner, K.D., J.D. Levine, and K.S. Topp, *Microtubule disorientation and axonal swelling in unmyelinated sensory axons during vincristine-induced painful neuropathy in rat*. J Comp Neurol, 1998. 395(4): p. 481-92.
72. Sweitzer, S.M., J.L. Pahl, and J.A. DeLeo, *Propentofylline attenuates vincristine-induced peripheral neuropathy in the rat*. Neurosci Lett, 2006. 400(3): p. 258-61.
73. Tappe-Theodor, A., and R. Kuner, *Studying ongoing and spontaneous pain in rodents—challenges and opportunities*. Eur. J. Neurosci. 2014. 39: p. 1881-1890.

74. Bhangoo, S.K., et al., *CXCR4 chemokine receptor signaling mediates pain hypersensitivity in association with anti-retroviral toxic neuropathy*. Brain Behav. Immun, 2007. 21: p. 581–591.
75. Hicks, C.W., and E. Selvin, *Epidemiology of peripheral neuropathy and Lower extremity disease in diabetes*. Curr. Diab. Rep, 2019. 19: p. 86.
76. Biessels, G. J., et al., *Phenotyping animal models of diabetic neuropathy: a consensus statement of the diabetic neuropathy study group of the EASD (Neurodiab)*. Journal of the Peripheral Nervous System, 2014. 19(2): p. 77–87.
77. Olukman, M., et al., *Treatment with NADPH oxidase inhibitor apocynin alleviates diabetic neuropathic pain in rats*. Neural Regen Res, 2018. 13(9): p. 1657–64.
78. Aley, K.O., and J.D. Levine, *Rapid onset pain induced by intravenous streptozotocin in therat*. J Pain, 2001. 2(3): p. 146–50.
79. Zhu, Y.F., et al., *Rat model of cancer-induced bone pain: changes in non-nociceptive sensory-neurons in vivo*. Pain reports, 2017. 2(4): p. e603.
80. Vecht, C.J., *Cancer pain: a neurological perspective*. Curr. Opin. Neurol, 2000. 13: p. 649–653.
81. Shimoyama, M., et al., *A mouse model of neuropathic cancer pain*. Pain, 2002. 99: p. 167–174.
82. Elramah, S., et al., *Spinal miRNA-124 regulates synaptodin and nociception in an animal model of bone cancer pain*. Scientific reports, 2017. 7(1): p. 1–13.
83. Bandera, A., et al., *HIV-associated neurocognitive impairment in the modern ART era: are we close to discovering reliable biomarkers in the setting of virological suppression?*. Frontiers in aging neuroscience, 2019. 187.
84. Burdo, T.H., and A.D. Miller, *Animal models of HIV peripheral neuropathy*. Future Virol, 2014. 9: p. 465–474.
85. Herzberg, U., and J. Sagen, *Peripheral nerve exposure to HIV viral envelope protein gp120 induces neuropathic pain and spinal gliosis*. J Neuroimmunol, 2001. 116(1): p. 29–39.
86. Cao, L., et al., *Murine immunodeficiency virus-induced peripheral neuropathy and the associated cytokine responses*. J. Immunol, 2012. 189: p. 3724–3733
87. Valek, L., G. Auburger, and I. Tegeder, *Sensory neuropathy and nociception in rodent models of Parkinson's disease*. Disease Models & Mechanisms, 2019. 12(6): p. dmm039396.
88. Faivre, F., et al., *The hidden side of Parkinson's disease: Studying pain, anxiety and depression in animal models*. Neuroscience & Biobehavioral Reviews, 2019. 96: p. 335–352.
89. Charles, K. A., et al., *Alteration of nociceptive integration in the spinal cord of a rat model of Parkinson's disease*. Movement Disorders, 2018. 33(6): p. 1010–1015.
90. Dina, O.A., et al., *Key role for the epsilon isoform of protein kinase C in painful alcoholic neuropathy in therat*. J Neurosci, 2000. 20(22): p. 8614–9.
91. Sereda, M.W., *Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A)*. Nat Med, 2003. 9: p. 1533–1537.
92. Meyer zu Horste, G, et al., *Anti-progesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy*. Ann Neurol, 2007. 61: p. 61–72.
93. Kankowski, S., C. Grothe, and K. Haastert-Talini, *Neuropathic pain: Spotlighting anatomy, experimental models, mechanisms, and therapeutic aspects*. European Journal of Neuroscience, 2021. 54(2): p. 4475–4496.
94. Sewell, R.D., *Neuropathic pain models and outcome measures: a dual translational challenge*. Annals of Translational Medicine, 2018. 6(Suppl 1).
95. Deuis, J. R., et al., *Methods used to evaluate pain behaviors in rodents*. Frontiers in molecular neuroscience, 2017: 284.
96. Tjolsen, A., et al., *An improved method for tail-flick testing with adjustment for tail-skin temperature*. J Neurosci Methods, 1989. 26: p. 259–265.
97. Dzoyem, J. P., et al., *Anti-inflammatory and anti-nociceptive activities of African medicinal spices and vegetables*. In *Medicinal spices and vegetables from Africa*. Academic Press, 2017: p. 239–270.
98. Bannon, A.W., and A.B., Malmberg., *Models of nociception: hot-plate, tail-flick, and formalin tests in rodents*. Current Protocols in Neuroscience, 2007. 41(1): p. 1–16.